FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Tullman Stephen A. 		2. Issuer Name and Ticker or Trading Symbol

Aclaris Therapeutics, Inc. [ ACRS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400 		3. Date of Earliest Transaction (MM/DD/YYYY)

10/13/2015
(Street)

MALVERN, PA 19355
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   10/13/2015     C    46188   (1) A   (2) 394014   I   By Trust   (3)
Common Stock                  521739   I   By NeXeption, LLC   (4)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock     (2) 10/13/2015     C         110000      (2)   (2) Common Stock   31884   $0.00   0   I   By Trust   (3)
Series B Preferred Stock     (2) 10/13/2015     C         31913      (2)   (2) Common Stock   9250   $0.00   0   I   By Trust   (3)
Series C Preferred Stock     (2) 10/13/2015     C         17437      (2)   (2) Common Stock   5054   $0.00   0   I   By Trust   (3)

Explanation of Responses:
( 1)  The total represents shares received upon conversion of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
( 2)  Effective upon the closing of the issuer's initial public offering of its common stock, each share of preferred stock automatically converted into 0.289855 shares of common stock. The preferred stock had no expiration date.
( 3)  These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which Mr. Tullman's spouse serves as the trustee.
( 4)  These shares are held by NeXeption, LLC, of which Mr. Tullman is the Manager.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Tullman Stephen A.
C/O ACLARIS THERAPEUTICS, INC.
101 LINDENWOOD DRIVE, SUITE 400
MALVERN, PA 19355 		X



Signatures
/s/ Brian F. Leaf, Attorney-in-fact 10/13/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2024 to Aug 2024 Click Here for more Aclaris Therapeutics Charts.
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Aug 2023 to Aug 2024 Click Here for more Aclaris Therapeutics Charts.